The Bruker Corp. (BRKR) Receives $24.39 Consensus Price Target from Brokerages

The Bruker Corp. (BRKR) Receives $24.39 Consensus Price Target from Brokerages

Bruker Corp. (NASDAQ:BRKR) has been assigned a consensus recommendation of “Hold” from the nineteen analysts that are currently covering the stock. One analyst has rated the stock with a sell recommendation, twelve have assigned a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $24.39.

A number of brokerages have issued reports on BRKR. Deutsche Bank AG reaffirmed a “hold” rating and issued a $24.00 price objective on shares of Bruker Corp. in a research report on Wednesday. Cantor Fitzgerald set a $28.00 price objective on shares of Bruker Corp. and gave the stock a “buy” rating in a research report on Wednesday, December 7th. JPMorgan Chase & Co. downgraded shares of Bruker Corp. from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $23.00 to $20.00 in a research report on Wednesday, December 14th. Zacks Investment Research raised shares of Bruker Corp. from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Monday, November 7th. Finally, Leerink Swann began coverage on shares of Bruker Corp. in a research note on Thursday, November 10th. They issued a “market perform” rating and a $21.00 target price on the stock.

Bruker Corp. (NASDAQ:BRKR) opened at 22.31 on Thursday. The company has a market capitalization of $3.57 billion, a PE ratio of 25.21 and a beta of 1.02. The stock’s 50 day moving average is $21.97 and its 200 day moving average is $22.39. Bruker Corp. has a one year low of $19.59 and a one year high of $29.85.

Bruker Corp. (NASDAQ:BRKR) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported $0.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.12. Bruker Corp. had a net margin of 9.02% and a return on equity of 26.05%. The business earned $393.90 million during the quarter, compared to the consensus estimate of $394.14 million. During the same period in the prior year, the firm posted $0.19 EPS. The firm’s quarterly revenue was down .6% compared to the same quarter last year. On average, analysts anticipate that Bruker Corp. will post $1.10 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, December 23rd. Shareholders of record on Monday, December 5th were paid a $0.04 dividend. This represents a $0.16 annualized dividend and a yield of 0.72%. The ex-dividend date was Thursday, December 1st. Bruker Corp.’s dividend payout ratio is presently 18.18%.

In related news, CEO Frank H. Laukien purchased 2,124 shares of the firm’s stock in a transaction dated Friday, November 25th. The shares were purchased at an average price of $22.90 per share, with a total value of $48,639.60. Following the acquisition, the chief executive officer now directly owns 37,699,606 shares of the company’s stock, valued at $863,320,977.40. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Frank H. Laukien purchased 4,725 shares of the firm’s stock in a transaction dated Thursday, December 15th. The stock was bought at an average cost of $21.22 per share, for a total transaction of $100,264.50. Following the acquisition, the chief executive officer now directly owns 37,704,331 shares in the company, valued at $800,085,903.82. The disclosure for this purchase can be found here. Corporate insiders own 35.80% of the company’s stock.

Institutional investors have recently modified their holdings of the company. ETRADE Capital Management LLC raised its position in shares of Bruker Corp. by 54.0% in the third quarter. ETRADE Capital Management LLC now owns 14,870 shares of the company’s stock worth $337,000 after buying an additional 5,216 shares during the last quarter. Piedmont Investment Advisors LLC bought a new position in shares of Bruker Corp. during the third quarter worth approximately $357,000. Price T Rowe Associates Inc. MD raised its position in shares of Bruker Corp. by 2.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 28,980,167 shares of the company’s stock worth $656,401,000 after buying an additional 661,337 shares during the last quarter. Cornerstone Capital Management Holdings LLC. raised its position in shares of Bruker Corp. by 1.6% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 408,819 shares of the company’s stock worth $9,259,000 after buying an additional 6,428 shares during the last quarter. Finally, Verition Fund Management LLC raised its position in shares of Bruker Corp. by 79.0% in the third quarter. Verition Fund Management LLC now owns 17,984 shares of the company’s stock worth $407,000 after buying an additional 7,936 shares during the last quarter. 67.70% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Corp. Company Profile

Bruker Corporation is a designer and manufacturer of scientific instruments, and analytical and diagnostic solutions. The Company’s operating segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Related posts

Leave a Comment